Subscribe To
Creso pharma completes integration of creso impactive ltd assets as it continues to broaden us horizons
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has completed the integration of Creso ImpACTIVE Ltd's assets into its product portfolio in a move that shoul...
November 14, 2021, 7:51 pm
Creso pharma completes integration of creso impactive ltd assets as it continues to broaden us horizons
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has completed the integration of Creso ImpACTIVE Ltd's assets into its product portfolio in a move that shoul...
November 14, 2021, 7:51 pm
Creso pharma completes integration of creso impactive ltd assets as it continues to broaden us horizons
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has completed the integration of Creso ImpACTIVE Ltd's assets into its product portfolio in a move that shoul...
November 14, 2021, 7:51 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine
License from Mid-Atlantic BioTherapeutics for IMT504 broadens Scope of Initial License Beyond Treatment...
October 7, 2021, 10:20 am
Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine
License from Mid-Atlantic BioTherapeutics for IMT504 broadens Scope of Initial License Beyond Treatment...
October 7, 2021, 10:20 am
Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine
License from Mid-Atlantic BioTherapeutics for IMT504 broadens Scope of Initial License Beyond Treatment...
October 7, 2021, 10:20 am
Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine
BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the...
October 7, 2021, 9:45 am
Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine
BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the...
October 7, 2021, 9:45 am
Curative biotechnology announces imt504 license for development of proprietary next-gen covid-19 vaccine
BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the...
October 7, 2021, 9:45 am